SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, will showcase its expanding focus on Dexcom CGM ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Highly anticipated presentation of results from the CONNECT randomized control trial will be presented during the ADA Scientific Sessions conference on Saturday, June 6 at 1:45 p.m. CDT. Early access ...

Dexcom anticipates that the findings could drive a shift in the standard of care for type 2 diabetes patients who do not use insulin.

Dexcom is poised to share new data on the benefits of its continuous glucose monitoring technology (CGM), which the company says reinforces the need to broaden CGM access beyond insulin-treated ...

FDA clears Dexcom Stelo as the first OTC CGM for children, raising new questions around app access, caregiver oversight, ...

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that Stelo, the first over-the-counter ...

Dexcom sponsored CONNECT randomized controlled trial expected to help establish new standard of care for CGM use by people with Type 2 diabetes not using insulin around the world. Showed use of Dexcom ...

DexCom, Inc. (NASDAQ:DXCM) will present new clinical findings, product advancements and strategic business initiatives reinforcing its commitment to improving care for people with all types of ...